Breast Cancer Research and Treatment

, Volume 114, Issue 3, pp 579–587 | Cite as

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

  • Heather-Jane Au
  • Kamran Golmohammadi
  • Tallal Younis
  • Shailendra Verma
  • Stephen Chia
  • Konrad Fassbender
  • Philip Jacobs
Epidemiology

Abstract

Purpose BCIRG 001 demonstrated prolonged disease-free (DFS) and overall survival (OS) but increased toxicity for adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in women with node positive breast cancer (BC). This study evaluates quality-adjusted survival and cost-effectiveness of adjuvant TAC versus FAC, taking downstream decisions and events into account, including palliative chemotherapy with taxanes. Methods We developed a Markov model for a cohort of women with node positive BC eligible for adjuvant anthracyclines. Data input included clinical and resource utilization data collected prospectively from BCIRG 001. Treatment decisions and outcomes with disease recurrence were based on a systematic literature review with validity reviewed by a national panel of Canadian BC oncologists. Direct costs for resource utilization following Canadian practice patterns were included. Unit costs were obtained from provincial cost list and published drug list prices. Utility scores were derived from the literature. An incremental cost-effectiveness ratio (ICER) in cost per quality-adjusted life-years (QALY) gained for TAC versus FAC was calculated. Results For 1,000 women with node positive BC, the model showed that TAC would lead to a gain of 313 QALY (370 life years) at an additional cost of $5.8 Million Canadian dollars (Cdn) compared to FAC, over a 10-year time horizon. The ICER of TAC versus FAC was $18,505.54 Cdn per QALY gained. Sensitivity analyses supported the robustness of the model. By one-way sensitivity analyses of over 50 model variables, 95% of the cumulative ICER variation was from $6,000 to $28,000 Cdn/QALY. By multivariate Monte Carlo simulation, there was a 70% probability that the ICER would be under $50,000 CdN/QALY. Conclusion For women with node positive BC, TAC improves DFS and OS compared to FAC and is a cost-effective adjuvant chemotherapy strategy.

Keywords

Breast cancer Cost effectiveness Adjuvant treatment Chemotherapy Taxanes 

Supplementary material

10549_2008_34_MOESM1_ESM.doc (29 kb)
Cost and their sources (DOCX 11 kb)

References

  1. 1.
    Canadian Cancer Society/National Cancer Institute of Canada (2006) Canadian cancer statistics 2006, Toronto, CanadaGoogle Scholar
  2. 2.
    Harris JR, Lippman ME, Morrow M et al (1996) Prognostic and predictive factors in diseases of the breast. Lippincott-Raven Publishers, Philadelphia, pp 461–485Google Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  4. 4.
    Adjuvant Therapy for Breast Cancer (2000) NIH consensus statement online. November 1–3; cited 2006, June 21, 17(4):1–23Google Scholar
  5. 5.
    O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(suppl 3):20–29PubMedCrossRefGoogle Scholar
  6. 6.
    Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRefGoogle Scholar
  7. 7.
    Blum JL, Dieras V, Mucci Lo Russo P et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768PubMedCrossRefGoogle Scholar
  8. 8.
    Zelek I, Barthier S, Riofrio M et al (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92:2267–2272PubMedCrossRefGoogle Scholar
  9. 9.
    Jones S, Erban J, OVermoyer B et al (2003) Randomized trial comparing docetaxel and paclitaxel in patients with metastatic breast cancer. Presented at the 26th annual San Antonio breast cancer symposiumGoogle Scholar
  10. 10.
    Papaldo P, Fabi A, Nardoni C et al (2003) Trastuzumab improves the prognosis in HER2-positive when compared with HER2-negative patients. Trastuzumab plus vinorelbine in HER2-positive versus vinorelbine alone in HER2-negative metastatic breast cancer patients. Breast Cancer Res Treat 82(suppl 1):S9Google Scholar
  11. 11.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  12. 12.
    Martin M, Pienkowski T, Mackey J et al (2003) TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients. BCIRG 001: 55 months followup. Presented at the 26th annual San Antonio breast cancer symposiumGoogle Scholar
  13. 13.
    Alberta Vital Statistics 2000–2003Google Scholar
  14. 14.
    Bedwinek J (1994) Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 4:260–269PubMedCrossRefGoogle Scholar
  15. 15.
    Clemons M, Danson S, Hamilton T et al (2001) Locoregionally recurrent breast cancer: incidence, risk factors and survival. Cancer Treat Rev 27:67–82PubMedCrossRefGoogle Scholar
  16. 16.
    Zielilnski CC (2003) Treatment choices for second-line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 81(suppl 1):S33–S36CrossRefGoogle Scholar
  17. 17.
    Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322–338PubMedCrossRefGoogle Scholar
  18. 18.
    Crown J, Dieras V, Kaufmann M et al (2002) Chemotherapy for metastatic breast cancer—report of a European expert panel. Lancet Oncol 3:719–727PubMedCrossRefGoogle Scholar
  19. 19.
    Fassbender K, Fainsinger R, Brenneis C et al (2005) Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993–2000. Palliat Med 19:513–520PubMedCrossRefGoogle Scholar
  20. 20.
    Brown RE, Hutton J, Burrell A (2001) Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091–1102PubMedCrossRefGoogle Scholar
  21. 21.
    Hayman JA, Hillner BE, Harris JR et al (2000) Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol 16:1022–1029Google Scholar
  22. 22.
    Leung PP, Tannock IF, Oza AM et al (1999) Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 17:3082–3090PubMedGoogle Scholar
  23. 23.
    Brown RE, Hutton J (1998) Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 9:899–907PubMedCrossRefGoogle Scholar
  24. 24.
    Martin SC, Gagnon DD, Zhang L et al (2003) Cost-utility analysis of survival with epoetin-alpha versus placebo in stage IV breast cancer. Pharmacoeconomics 21:1153–1169PubMedCrossRefGoogle Scholar
  25. 25.
    Drummond MF, Scupher MJ, Torrance GW et al (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University press, OxfordGoogle Scholar
  26. 26.
    Case Mix number 297, Alberta Health and Wellness, costs in Alberta, 2002Google Scholar
  27. 27.
    Hurley SF, Huggins RM, Snyder RD et al (1992) The cost of breast cancer recurrences. Br J Cancer 65:449–455PubMedGoogle Scholar
  28. 28.
    Martin M, Lluch A, Segui MA (2004) Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. J Clin Oncol; 22(suppl 14):620. Proc ASCO (Post-Meeting Edition)Google Scholar
  29. 29.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trustuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRefGoogle Scholar
  30. 30.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRefGoogle Scholar
  31. 31.
    TreeAge software Inc. (2005) Williamstown, MAGoogle Scholar
  32. 32.
    Hirth RA, Chernew ME, Miller E et al (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Health Econ 20:332–342Google Scholar
  33. 33.
    Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook, 6th edn. Springer, New YorkGoogle Scholar
  34. 34.
    Smith TJ, Khatcheressian J, Lyman GH (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guidelines. J Clin Oncol 24:3187–3205PubMedCrossRefGoogle Scholar
  35. 35.
    Hillner BE, Weeks JC, Desch CE et al (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79PubMedGoogle Scholar
  36. 36.
    Neyt M, Albrecht J, Cocquyt V (2006) An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 17:381–390PubMedCrossRefGoogle Scholar
  37. 37.
    Elkin EB, Weinstein MC, Winer EP et al (2004) HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 22:854–863PubMedCrossRefGoogle Scholar
  38. 38.
    Hillner BE, Schrag D, Sargent DJ et al (2005) Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer 104:1871–1084PubMedCrossRefGoogle Scholar
  39. 39.
    Rocconi RP, Case AS, Straughn JM et al (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107:536–543PubMedCrossRefGoogle Scholar
  40. 40.
    Ubel PA, Hirth RA, Chernew ME et al (2003) What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med 163:1637–1641PubMedCrossRefGoogle Scholar
  41. 41.
    Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Heather-Jane Au
    • 1
    • 2
  • Kamran Golmohammadi
    • 2
  • Tallal Younis
    • 3
  • Shailendra Verma
    • 4
  • Stephen Chia
    • 5
  • Konrad Fassbender
    • 2
  • Philip Jacobs
    • 2
  1. 1.Cross Cancer InstituteEdmontonCanada
  2. 2.Faculty of Medicine and DentistryUniversity of AlbertaEdmontonCanada
  3. 3.Queen Elizabeth II Health Sciences CentreHalifaxCanada
  4. 4.Ottawa Hospital Integrated Cancer Centre ProgramOttawaCanada
  5. 5.Vancouver Cancer CentreVancouverCanada

Personalised recommendations